Jane Street Group LLC Sells 5,299 Shares of Solid Biosciences Inc. (NASDAQ:SLDB)

Jane Street Group LLC lessened its holdings in shares of Solid Biosciences Inc. (NASDAQ:SLDB) by 20.3% during the 3rd quarter, HoldingsChannel reports. The firm owned 20,810 shares of the company’s stock after selling 5,299 shares during the period. Jane Street Group LLC’s holdings in Solid Biosciences were worth $145,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP lifted its stake in Solid Biosciences by 8.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 70,827 shares of the company’s stock valued at $402,000 after acquiring an additional 5,287 shares in the last quarter. MetLife Investment Management LLC lifted its stake in Solid Biosciences by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock valued at $95,000 after acquiring an additional 7,719 shares in the last quarter. American Century Companies Inc. lifted its stake in Solid Biosciences by 39.9% in the 2nd quarter. American Century Companies Inc. now owns 34,557 shares of the company’s stock valued at $196,000 after acquiring an additional 9,853 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in Solid Biosciences in the 3rd quarter valued at approximately $71,000. Finally, Point72 DIFC Ltd bought a new stake in Solid Biosciences in the 2nd quarter valued at approximately $58,000. Institutional investors own 81.46% of the company’s stock.

Wall Street Analysts Forecast Growth

SLDB has been the topic of several research reports. Wedbush started coverage on Solid Biosciences in a research note on Friday, December 13th. They issued an “outperform” rating and a $16.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Friday. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price target on shares of Solid Biosciences in a research report on Monday, November 11th. Truist Financial started coverage on Solid Biosciences in a research report on Wednesday, January 8th. They set a “buy” rating and a $16.00 price target on the stock. Finally, JMP Securities started coverage on Solid Biosciences in a research report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price target on the stock. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $15.30.

Solid Biosciences Trading Down 10.1 %

SLDB stock opened at $3.31 on Tuesday. The firm has a market capitalization of $132.25 million, a PE ratio of -1.09 and a beta of 2.05. Solid Biosciences Inc. has a 1-year low of $3.28 and a 1-year high of $15.05. The business’s 50 day simple moving average is $4.88 and its 200 day simple moving average is $6.61.

Solid Biosciences (NASDAQ:SLDB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.12). As a group, sell-side analysts predict that Solid Biosciences Inc. will post -2.85 EPS for the current fiscal year.

Insider Buying and Selling at Solid Biosciences

In other news, COO David T. Howton sold 5,072 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total transaction of $28,403.20. Following the completion of the sale, the chief operating officer now directly owns 15,663 shares in the company, valued at approximately $87,712.80. This represents a 24.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Alexander Cumbo sold 11,114 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $62,238.40. Following the sale, the chief executive officer now owns 38,484 shares of the company’s stock, valued at approximately $215,510.40. The trade was a 22.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 28,848 shares of company stock valued at $155,852 in the last ninety days. 13.63% of the stock is currently owned by corporate insiders.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.